What medications can be used to treat hyperphosphatemia in an adult patient?

Medications for Hyperphosphatemia

For adult patients with hyperphosphatemia, phosphate binders are the primary pharmacologic treatment, with the choice depending on underlying etiology, calcium levels, and CKD stage.

First-Line Treatment Approach

Phosphate Binders

Phosphate binders remain the cornerstone of hyperphosphatemia management when dietary restriction and adequate dialysis are insufficient 1, 2. The selection should be guided by:

• Serum calcium levels: Avoid calcium-based binders if calcium is elevated or normal-high
• CKD stage: Non-calcium binders preferred in advanced CKD due to vascular calcification risk
• Tolerability: Gastrointestinal side effects are common across all binders

Specific Binder Options

Calcium-based binders (calcium carbonate, calcium acetate):

• Effective at lowering phosphate but risk hypercalcemia and vascular calcification 3
• Should be avoided in patients with elevated calcium or significant vascular calcification 4, 5
• Lower cost but concerning long-term cardiovascular risks

Non-calcium binders:

• Sevelamer: Reduces vascular calcification progression; main adverse effects are gastrointestinal 6, 3
• Lanthanum carbonate: Effective with tissue deposition appearing clinically irrelevant long-term 6, 3
• Iron-based binders (ferric citrate): Evidence suggests best efficacy/acceptability profile - fewer treatment withdrawals and effective phosphate lowering 2
• Magnesium carbonate: Showed best phosphorus-lowering effect in network meta-analysis 2

Novel Therapies

Tenapanor

Tenapanor (NHE3 inhibitor) blocks paracellular phosphate absorption and is FDA-approved for hyperphosphatemia in kidney failure 1:

• Can be combined with phosphate binders for dual-mechanism treatment
• Achieved significantly greater phosphate reduction when added to binders (-0.84 vs -0.19 mg/dL, p<0.001) 7
• Main adverse effect is diarrhea (3.4% discontinuation rate) 7
• Lower pill burden compared to traditional binders 1, 6

Special Circumstances

Secondary Hyperparathyroidism with Hyperphosphatemia

When hyperphosphatemia occurs with elevated PTH 5:

1. First: Evaluate and correct modifiable factors - vitamin D deficiency, hypocalcemia, high phosphate intake
2. Phosphate binders: Initial treatment to lower phosphate load
3. Calcimimetics: Consider for severe hyperparathyroidism, but use cautiously due to hypocalcemia risk (7-9% severe hypocalcemia rate) 4
4. Active vitamin D analogues: Reserve for CKD G4-G5 with severe, progressive hyperparathyroidism; not routinely recommended due to hypercalcemia risk (22-43% incidence) 5

Dialysis Patients

For maintenance dialysis patients with persistent hyperphosphatemia despite binders 8, 7:

• Optimize dialysis adequacy first
• Consider combination therapy: tenapanor plus phosphate binders 7
• Adjust dialysate calcium concentration (1.25-1.50 mmol/L neutral calcium balance) 4

Rare Genetic Causes (FGF23 Pathway Disorders)

For treatment-resistant hyperphosphatemia due to FGF23 loss-of-function mutations 9:

• Denosumab (RANKL inhibitor) showed marked sustained phosphate reduction
• Monitor for hypocalcemia (common but usually asymptomatic)
• Conventional therapies (binders, dietary restriction) typically ineffective in these cases

Critical Monitoring

• Serum phosphate: Target varies by CKD stage; no universal optimal level established 4, 5
• Calcium levels: Especially with calcium-based binders or calcimimetics
• PTH trends: Progressive rise indicates need for intervention 5
• Kidney function: Reduced eGFR <60 mL/min requires careful phosphate monitoring 10

Common Pitfalls

• Pill burden: All phosphate binders require multiple daily doses, leading to poor adherence 1, 11
• Aluminum hydroxide: Limit to 1-2 days maximum due to cumulative toxicity risk 8
• Calcium overload: Prolonged calcium-based binder use accelerates vascular calcification 4, 3
• Inadequate protein intake: Overly restrictive phosphate diets risk malnutrition 1